Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
ISTH Profile picture
ISTH
@isth
The International Society on Thrombosis & Haemostasis advances understanding, prevention, diagnosis & treatment of conditions related to thrombosis & hemostasis
Sep 29, 2022 • 15 tweets • 6 min read
🧵Your 18-year-old patient has severe hemophilia B, no history of inhibitors, and has low titer AAV antibodies. He has been treated on-demand for the past 5 years. Would he be a candidate for gene therapy currently in clinical trials? #Tweetorial #MedEd #GeneTherapy #Hemophilia Understanding who might be a candidate for gene therapy for #hemophilia (GTH) is critical. Why? This new therapy has been approved by regulatory authorities in Europe and is under consideration in the US. So who is eligible? Review: genetherapy.isth.org/9153-tweetoria… #cme_accreditation
Aug 29, 2022 • 14 tweets • 5 min read
TWEETORIAL: Understanding the basics of immune thrombocytopenic purpura (ITP) can help understand options for diagnosis and treatment. Read on to refresh you knowledge, or explore our course on acquired thrombocytopenia at academy.isth.org/isth/#!*menu=6… How would you characterize your interest in ITP?
Jul 26, 2022 • 15 tweets • 4 min read
Exciting new treatments for #hemophilia A and B are in development, one of which is gene therapy. Image How would you characterize your interest in hemophilia?
Jun 22, 2021 • 12 tweets • 4 min read
Despite thromboprophylaxis, a patient being treated for cancer develops venous thromboembolism (VTE). Now what? How would you answer the following?
Which statement most accurately reflects the ASH 2021 and ASCO guidelines for treatment of acute VTE in patients with cancer?
Jun 17, 2021 • 11 tweets • 4 min read
We know that venous thromboembolism (VTE) is more common in patients with cancer (3.4%) compared to the general population (1%) and that the incidence has been gradually increasing over the past 20 years.

But is VTE in cancer patients preventable?

Read on to find out. Here's a question:
Based on current guidelines from ITAC, ISTH, and ASH, DOACs (apixaban and rivaroxaban) are recommended as primary prophylaxis for patients with cancer who are ambulatory, receiving, or starting therapy, and have a Khorana score (KS) for VTE risk that is?